The Futura Medical placing announced this week is raising £1.6 million, but the deeper news sitting alongside it may matter more to holders of FUM shares: the company has simultaneously launched a Formal Sale Process (FSP), opening the door to a potential sale of the business or its assets.
Futura Medical, the AIM-listed (AIM: Alternative Investment Market, the London Stock Exchange’s market for smaller companies) developer of Eroxon, its erectile-dysfunction treatment, is issuing 801,000,000 new ordinary shares at 0.2 pence each through a placing and subscription. On top of that, a conditional retail offer via the BookBuild platform could add up to a further £150,000 through the issue of up to 75,000,000 new ordinary shares at the same price.
At 0.2p, the issue price represents the kind of number that makes existing shareholders wince. Dilution (the reduction in each share’s proportional claim on the company when new shares are issued) at this scale is material.
What the Futura Medical Placing Actually Involves for Broker Turner Pope
The fundraise’s structure hands meaningful rewards to the company’s broker, Turner Pope Investments. According to the full announcement on the London Stock Exchange (LSE), Turner Pope’s remuneration under the placing agreement includes commissions calculated on shares allotted, a corporate finance fee, and certain other fees.
Beyond those fees, Turner Pope will receive up to 204,875,000 warrants, known as the 2026 Warrants, exercisable into ordinary shares at 0.2 pence per share at any time until the fifth anniversary of their issuance. These replace and cancel warrants previously held by the broker.
The backstory on those prior warrants: in a November 2025 fundraise of £2.75 million, Turner Pope had received warrants over 34,375,000 ordinary shares at an exercise price of 1 pence per share. Those are now being cancelled and replaced by the 2026 Warrants, which carry a lower exercise price and cover far more shares.
The Formal Sale Process: Why It Could Be the Bigger Story
Alongside the capital raise, Futura Medical’s board has launched a Formal Sale Process and M&A (mergers and acquisitions) review. The stated rationale is that the current market valuation is not seen to reflect the portfolio’s strategic potential, particularly for WSD4000, a product with estimated peak annual consumer sales exceeding US$400 million, according to the company’s own announcement on Investegate.
A Formal Sale Process under the UK Takeover Code requires a company to make a public announcement that it is in discussions with potential acquirers. Once the FSP is launched, any party that wishes to make an offer must do so within a defined timetable. For shareholders, this creates a binary outcome: a transaction is agreed and value is crystallised, or the process concludes without a deal and the shares continue trading on their existing trajectory.
Given that trajectory, context helps. Futura Medical’s board expected FY25 revenue of £1.7 million, ahead of prior guidance of £1.3 to £1.4 million, with year-end net cash of £3.4 million following the November 2025 raise, according to a trading update published via Investor Meet Company. Revenue growing ahead of guidance is a positive signal, but the net cash position is being eroded by each successive fundraise at these prices, and the November 2025 raise was itself at terms that diluted holders.
The 0.2p issue price in this latest Futura Medical placing is the same exercise price on the 2026 Warrants, which means Turner Pope can convert its warrants for no premium to the placing price. If the FSP produces a buyer willing to pay meaningfully above 0.2p per share, those warrants become valuable quickly. If no deal materialises, existing shareholders have absorbed further dilution in exchange for roughly six weeks of additional runway.
The retail offer component via BookBuild gives private investors a chance to participate at the same 0.2p price as institutional placees, which is at least consistent treatment. Whether participating at that price makes sense depends entirely on what the FSP produces. A sale at a price that reflects WSD4000’s commercial potential would be transformative for holders at current levels; a failed process would leave a heavily diluted register and a small, cash-constrained business.
The FSP outcome is the only number that matters now. Watch for any announcement of an approach, a named bidder, or a deadline extension under the Takeover Code, all of which would sharpen the picture considerably.
